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Abstract
The adapter protein metastasis suppressor 1 (MTSS1) is implicated as a tumor suppressor
or tumor promoter, depending on the type of solid cancer. Here, we identified Mtss1 expres-
sion to be increased in AML subsets with favorable outcome, while suppressed in high risk
AML patients. High expression of MTSS1 predicted better clinical outcome of patients with
normal-karyotype AML. Mechanistically, MTSS1 expression was negatively regulated by
FLT3-ITD signaling but enhanced by the AML1-ETO fusion protein. DNMT3B, a negative
regulator of MTSS1, showed strong binding to the MTSS1 promoter in PML-RARA positive
but not AML1-ETO positive cells, suggesting that AML1-ETO leads to derepression of
MTSS1. Pharmacological treatment of AML cell lines carrying the FLT3-ITD mutation with
the specific FLT3 inhibitor PKC-412 caused upregulation of MTSS1. Moreover, treatment of
acute promyelocytic cells (APL) with all-trans retinoic acid (ATRA) increased MTSS1
mRNA levels. Taken together, our findings suggest that MTSS1 might have a context-de-
pendent function and could act as a tumor suppressor, which is pharmacologically target-
able in AML patients.
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Introduction
Acute myeloid leukemia (AML) comprises a heterogeneous group of malignancies that are
characterized by a maturational block of myeloid cell development and can be classified ac-
cording to their distinct phenotypes and / or oncogenes. Although therapeutic interventions in
AML have steadily improved, the implementation of disease specific treatment strategies is still
inapplicable for most AML entities. Moreover, acquisition of novel mutations in addition to in-
sufficient disease eradication of malignant self-renewing cells may result in subsequent relapse.
In order to achieve better control of AML stem cells and improve long-term survival of patients
a better understanding of the pathogenesis in various AML subtypes is required [1]. Different
AML subtypes are a result of unique mutations, such as FLT3-ITD conferring resistance to
conventional therapy and correlate with poor clinical outcome [2]. In comparison, other muta-
tions such as the translocations t(8;21) or t(15;17) resulting in the AML1-ETO or PML-RARα
fusion molecules, respectively, are associated with a lower risk and far better prognosis [3].
Therefore, the identification of potential tumor suppressors or oncogenes which may be ei-
ther suppressed or activated by FLT3-ITD signaling in direct contrast to AML1-ETO patients
could help to improve our understanding of the unique signaling patterns. The identification
of such molecules would help in the development of more personalized and successful
therapeutic approaches.
Recently, we have described genetic mutations and epigenetic alterations (“epimutations”)
in the gene encoding for DNA methyltransferase 3A (DNMT3A) [4] which affect DNMT3A
isoform expression and are associated with an inferior prognosis in AML, clustering together
with FLT3-ITD mutations but not with AML1-ETO translocations. Overexpression of
DNMT3B, a related gene, was shown to confer a poor prognosis in AML [5]. However, the
mechanism of how DNMT3B affects AML cells is currently unknown. Interestingly, the adapt-
er molecule and potential tumor suppressor molecule Metastasis Suppressor 1 (MTSS1) has re-
cently been described to be a transcriptional target of DNMT3B in hepatocellular cancer [6].
Moreover, the authors demonstrated that the multi domain adapter molecule MTSS1 functions
as a tumor suppressor in vivo. MTSS1 has previously been shown to be downregulated in me-
tastases of a variety of solid tumors. Moreover, low MTSS1 expression levels confer a poorer
prognosis in breast and ovarian cancer and higher expression levels correlate with improved
overall survival rates [7,8]. The prognostic value of MTSS1 expression has also been demon-
strated for esophageal squamous cell carcinoma in which patients with high MTSS1 expression
levels had a favorable prognosis compared to those who had reduced MTSS1 expression levels
[9]. However, in colorectal cancer high MTSS1 expression has recently been shown to correlate
with poor prognosis [10] and to be associated with disease progression in a subset of human
melanomas [11]. The exact role of this adaptor molecule that links intracellular signaling path-
ways with actin remodeling [7];[12];[13] is still under debate and may likely depend on the cell
type and molecular context. Recent genetic knockout studies for MTSS1 suggest an important
role in the hematopoietic system. Specifically, MTSS1 knockout mice have an increased pro-
pensity to develop aggressive B cell lymphomas [14]. This suggests that MTSS1 has a tumor
suppressing function in hematopoietic malignancies. However, whether MTSS1 plays a role in
the pathogenesis of myeloid neoplasms and how MTSS1 expression and MTSS1-mediated sig-
naling are altered in the context of specific hematopoietic oncogenes remains unclear.
Here, we provide evidence that MTSS1 expression is differently expressed in specific AML
subsets. Interestingly, low MTSS1 expression correlated with decreased overall survival in nor-
mal-karyotype AML, possibly involving DNMT3B overexpression. Moreover, Mtss1 downre-
gulation may be an indicator or involved in the pathogenesis of unfavorable AML subtypes, as
MTSS1 expression was low in FLT3-ITD but high in AML1-ETO associated AML. Finally, the
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expression of MTSS1 could be reverted by pharmacological inhibition which specifically targets
either the PML-RARα or FLT3-ITD oncogenes leading to increased expression of MTSS1.
Materials and Methods
Primary human samples and human cell lines
The human and murine cell lines were obtained from DSMZ, Braunschweig, Germany. We
maintained human leukemia cells (U937, K562, NB4, Kasumi-1 and MV4-11, in Roswell Park
Memorial Institute medium (RPMI-1640, Invitrogen, Carlsbad, CA) with GlutaMAX contain-
ing 10% fetal bovine serum, 100 IU ml-1 penicillin and 100 μg ml-1 streptomycin at 37°C in a
humidified incubator with 5% CO2. The murine 32D cell lines were cultured in RPMI with L-
glutamine and 10% FCS; 32D cultures were supplemented with murine IL-3 obtained from su-
pernatant of WEHI-3B cells. Stably transfected U937 cell lines expressing in a Zn2+-inducible
fashion PML-RARA or empty vector as control have been previously described [15]. Written
consent was obtained from all patients before sample analysis, and the study was approved by
the ethics committee of the Faculty of Medicine, Wilhelms-University of Muenster.
Quantitative RT-PCR and genomic PCR
RNA was isolated using RNAeasy kit (QIAGEN) according to the manufacturer's instructions.
RNA (1 μg) was reverse transcribed using oligo-d(T) primer and random hexamers. cDNA
was generated with M-MLV reverse transcriptase (Promega) for 1 hour at 42°C. The quantita-
tive reverse-transcribed polymerase chain reaction (qRT-PCR) for gene expression was per-
formed using either a combination of Primer and 6-carboxyfluorescein (FAM)-labeled Probe
or SYBER Green. Commercially available TaqMan assays (Applied Biosystems by life Technol-
ogies) were used for human (HS00207341_m1) or murine MTSS1 (Mm00460614_m1) expres-
sion analysis. For relative quantification we included detection of GAPDH as a housekeeping
gene and calculated the expression of our gene of interest as percent of GAPDH.
Western blotting
After harvest, 2x106 cells were washed twice with PBS and lysed in CelLytic MT buffer (Sigma-
Aldrich) supplemented with Mini Complete protease inhibitor (Roche), 1% phosphatase inhib-
itor cocktail (Calbiochem), and 1mM PMSF. After 10 min incubation on ice and centrifugation
at 11,000g for 10 min at 4°C, the protein concentration was determined by BCA Assay
(Thermo Scientific). Protein samples were loaded on 10% Bis-Tris gels and transferred on a
PVDF membrane (BioRad). For protein detection of MTSS1 or GAPDH primary antibodies
from Cell Signaling (#4386, clone N747, 1:1000 dilution) or Santa Cruz (sc-32233, clone 6C5,
1:2000 dilution) were used followed by a secondary goat anti-rabbit HRP conjugated antibody
(Dako, 1:10000) and light emission analysis using Fusion SL system (PeqLab).
Pharmacological inhibitor and differentiation studies
0.5μMAll-trans retinoic acid (Stock 10μM in DMSO; Sigma-Aldrich) was added as differentia-
tion agent to NB4, U937 PMT control and U937 PMT RARα cells. Control samples were incu-
bated using equivalent volume of DMSO vehicle. Cells were harvested at the indicated time
points and subjected to quantitative RT-PCR or FACS analysis. PKC-412 was similarly dis-
solved in DMSO and cells were treated at indicated time points.
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Flow cytometry
For flow cytometry analysis 2x105 cells were harvested and washed using phosphate buffered
saline (PBS) including 2% FCS. Cells were resuspended in 100 μL PBS/2%FCS, and incubated
with either PE-labeled anti-CD11b (clone M1/7015.1, Cymbus Biotechnology) or PE-labele-
danti-CD11c (clone B-ly6, BD Biosciences) antibody for 10 minutes on ice for staining of gran-
ulocytes or macrophages. For detection of unspecific binding cells were incubated with PE-
labeled Mouse IgG1-control antibody. All antibodies were used in a 1:100 dilution. Cells were
washed, resuspended in 400μl PBS/2%FCS and analyzed by flow cytometry (FACSCalibur, BD
Biosciences). We therefore first gated on living cells via SSC/FSC profile and subsequently ana-
lyzed surface expression of the respective antigen using 1x104 gated viable cells.
Renilla / Firefly Reporter System
The Dual-Luciferase Reporter Assay System (Promega) was used to measure luciferase activity
of cells transfected with indicated MTSS1 constructs using a Synergy2TM luminometer (Bio-
Tek, Winooski, VT). Sample preparation was performed according to the manufactures proto-
col. Luciferase activities are shown as a Firefly/Renilla ratio.
Chromatin immunoprecipitation (ChiP)
ChIP experiments were performed using the Active Motif ChIP-IT Express Chromatin Immu-
noprecipitation Kit. 5x106 NB4 or Kasumi-1 cells were fixed with formaldehyde for 10 minutes,
lysed and DNA was sheared using a Bioruptor Pico (Diagenode) for 12 cycles (30 sec on, 30 sec
off). Immunoprecipitation was conducted with a DNMT3B antibody (Santa Cruz; H-230) or
an IgG antibody (Abcam) as control to test for unspecific binding. Interaction between
DNMT3B protein and MTSS1 promoter was analyzed by quantifying precipitated ChIP-DNA
using real-time PCR and SYBR Green. Percent of bound DNA was calculated and compared to
an input control. (2-(Ct (IP) − Ct (Input))). Primers used for amplification of the precipitated DNA
fragments were published previously [6].
Patient outcome and gene expression microarray data
Gene expression microarray and patient outcome data were obtained from the GEO database
accession numbers GSE1159 [16], GSE15646 [17], GSE8023[18] and GSE12417[19]. Data was
processed with Cluster and visualized by Treeview software 1.6. Expression level of a gene in a
sample was determined by the average of expression values from multiple probe sets on the
array representing this gene.
Statistical analysis
Statistical analyses were performed using Student t test (normal distribution) or Mann-Whit-
ney U test (when normal distribution was not given). P less than .05 was considered as indicat-
ing statistically significant differences.
Results
MTSS1 is overexpressed in AML1-ETO+ but downregulated in
FLT3-ITD+ AML
The prognostic value of MTSS1 downregulation has been demonstrated for solid tumors such
as breast and prostate cancer. Moreover, functional data have revealed a tumor suppressing
function also in hematopoietic malignancies. To study the function of MTSS1 in AML subsets
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we used publicly available gene expression data [16] and analyzed the expression of DNMT3A,
DNMT3B, and MTSS1 in different AML subsets. We found that MTSS1 was strikingly overex-
pressed in patients carrying the favorable t(8;21) and inv(16) translocations compared to pa-
tients with FLT3-ITD mutation correlating with poor prognosis as well as t(15;17) (Fig 1A and
1B). MTSS1 expression was not altered in the cluster with RAS mutations only, but was in-
creased in the cluster of patients which harbored both RAS mutations and a t(8;21) transloca-
tion, suggesting a link between the AML1-ETO fusion molecule and MTSS1 (Fig 1A). Further
proof that MTSS1 expression is differentially regulated by oncogenic alterations in AML cells
came from the fact that MTSS1 mRNA levels were significantly higher in an AML cell line car-
rying the t(8;21) translocation (Kasumi-1) than in FLT3-ITD positive cells (MV4-11),
PML-RARα t(15;17) positive cells (NB4) or U937 cells (Fig 1C). These effects on MTSS1 RNA
translated into significant differences in MTSS1 protein levels in AML1-ETO positive vs.
FLT3-ITD and PML-RARα positive cell lines, as detected by Western blotting (Fig 1D).
MTSS1 expression correlates with improved survival in normal
karyotype AML
In our cohort of patients with AML, MTSS1 expression was confirmed by qRT-PCR to be in-
creased in t(8;21) or inv(16) AML samples as compared to t(15;17) (Fig 2A). Interestingly, when
we analyzed samples from patients with normal karyotype AML, we found MTSS1 expression to
be highly variable (Fig 2A). We reasoned that since high MTSS1 expression was found in prog-
nostically favorable AML subgroups, the prognosis of patients with normal karyotypes may dif-
fer according to their level ofMTSS1 expression. Indeed, when 163 patients with normal
karyotype-AML in the German AMLCG 1999 clinical trial [19] were separated into two groups
depending on whether their expression of MTSS1 is below or above the MTSS1-probeset, medi-
an across all samples, patients with high expression levels ofMTSS1 (MTSS1HI) showed a signifi-
cantly improved overall survival suggesting that MTSS1 is a predictor of favorable outcome (Fig
2B). In the same clinical trial, high expression ofDNMT3B, which has been shown to impede
MTSS1 expression, showed reversed patterns and correlated with decreased overall survival (Fig
2C). To study if there is a link between MTSS1 and DNMT3B, we segregated the patients in two
groups based either on their high MTSS1 and low DNMT3B (MTSS1HI—DNMT3BLO) or low
MTSS1 and high DNMT3B expression (MTSS1LO—DNMT3BHI). Strikingly, patients with high
MTSS1 and low DNMT3B expression showed a highly significant increased overall survival rate
compared to those with lowMTSS1 and high DNMT3B expression (Fig 2D). DNMT3B binding
to the MTSS1 promoter has previously been described to occur at -864/-645 bp upstream of the
transcriptional start site and acts as a mechanism that allows for transcriptional suppression of
MTSS1 in hepatocellular carcinoma [6]. To analyze for a direct binding of DNMT3B to the re-
spective MTSS1 promoter region in AML, we performed chromatin immunoprecipitation ex-
periments. We previously detected increased MTSS1 expression in t(8;21) positive cells but not
in t(15;17) positive AML (Fig 1B and 1C) and therefore compared DNMT3B binding to the
MTSS1 promoter using these two cell types (Fig 2E). We confirmed binding of DNMT3B to the
MTSS1 promoter region (-864/-645) in t(15;17) positive cells. Interestingly, this interaction was
not detectable in t(8;21) MTSS1 highly expressing AML cells. These data confirm a direct link
between DNMT3B activity and decreased MTSS1 expression also in a subset of AML.
MTSS1 expression is upregulated after ATRA-mediated differentiation in
t(15;17) AML
The t(15;17) translocation is only found in the acute promyelocytic leukemia (APL) subset of
AML and results in the PML-RARα fusion molecule. The oncogenic protein induces a
MTSS1 as a New Biomarker in AML Subtypes
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Fig 1. MTSS1 is upregulated in t(8;21) and inv(16) AML patients. The gene expression profiling of MTSS1, DNMT3B and DNMT3A in different AML
subsets (GEO accession number GSE1159) is shown (A andB). MTSS1mRNA levels were measured by qRT-PCR in human AML cell lines carrying either
a FLT3-ITD mutation (MV4-11), t(15;17) (NB4), t(8;21) (Kasumi-1) or undefined genetic changes (U937) in relative expression to GAPDH (n = 3; C) which
was verified at the protein level by Western Blot analysis using GAP-DH as a loading control (D).
doi:10.1371/journal.pone.0125783.g001
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Fig 2. MTSS1 expression correlates with better clinical outcome of normal karyotype-AML patients.MTSS1mRNA levels were measured in patient-
derived AML samples (n = 66) with either a Normal Karyotype (NK, n = 38), t(15;17) (n = 15), t(8;21) (n = 5) or inv(16) (n = 8) aberration by qRT-PCR and are
expressed as % of GAPDH (A). Using the Leukemia Gene Atlas [37] and data from the German AMLCG 1999 clinical trial [19], two groups of patients (above
vs. below the median expression of MTSS1) were analyzed for overall survival (OS) in NK AML patients (n = 163, logrank test P = 0.03; GEO accession
number GSE12417; B). Similarly, in the same trial, patients with a DNMT3B expression above vs. below the median were analyzed for survival (n = 163,
logrank test P = 0.04; C). We then segregated patients into two groups based on their MTSS1 and DNMT3B expression levels according to high MTSS1 and
low DNMT3B or low MTSS1 and high DNMT3B expression and assessed overall survival (AMLCG 1999, n = 163, logrank test P = 0.006;D). Binding of
DNMT3B to the MTSS1 promoter was analyzed by chromatin immunoprecipitation experiments using NB4 and Kasumi-1 cells. Precipitated ChIP-DNA was
quantified using real-time PCR and SYBRGreen for MTSS1 promoter region -864/-645 (E).
doi:10.1371/journal.pone.0125783.g002
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differentiation block that can be reversed by treatment with all-trans retinoic acid (ATRA)
[20]. Our findings suggest that MTSS1 is downregulated in APL patients (Figs 1B and 2A). To
study if MTSS1 expression is affected by the presence of PML-RARA, we used a zinc-inducible
system of stable PML-RARα overexpression in human AML cells (U937, PR9), which usually
do not carry the PML-RARα fusion molecule. Upon induction of ectopic PML-RARα expres-
sion by the addition of zinc to the cell cultures, MTSS1 mRNA levels significantly decreased in
PML-RARα expressing but not control cells (U937, PMT empty vector), suggesting a direct
link and potential tumor suppressive function of MTSS1 in PML-RARα positive cells (Fig 3A).
We next studied if MTSS1 mRNA levels could be rescued by treatment with ATRA. Treatment
with ATRA both in these stably transfected PML-RARα expressing U937 cells as well as in t
(15;17)-carrying human AML cells (NB4) led to differentiation as verified by increased expres-
sion of myeloid markers such as CD11b and CD11c after 72 hours of treatment (S1 Fig). More
importantly, when NB4 cells were treated with ATRA, MTSS1 mRNA levels were significantly
increased 2.9-fold after 48 hours and progressed after 72 hours of treatment to 7.8-fold (Fig
3B). In line with these data, there was a trend of increasing Mtss1 levels (1.9-fold; p = 0.05) in
U937 PR9 cells after 72 hours of treatment but not in empty vector U937 control cells (S2 Fig).
These findings suggest that MTSS1 expression is downregulated by PML-RARα and that this
can be reverted by ATRA also in patients with APL.
Fig 3. MTSS1 expression is increased by ATRA treatment in t(15;17) AML.MTSS1mRNA levels were measured in human AML cells (U937) transduced
with either empty vector control (PMT Control) or an inducible PML-RARα (PR9) after 24 hours of activation with zinc (Zn) by qRT-PCR (n = 3; A). Similarly,
MTSS1mRNA levels were measured after treatment with all-trans retinoic acid (0.5μMATRA) or 0.5μMDMSO control after 48 and 72 hours in human AML
cells carrying the PML-RARα translocation (NB4) (n = 3; B).
doi:10.1371/journal.pone.0125783.g003
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MTSS1 expression is positively regulated by AML1-ETO in AML patients
Since MTSS1 expression was high in t(8;21) positive cell lines and primary AML samples, we
next studied whether there was a direct link between MTSS1 and AML1-ETO. Using publicly
available databases, we could show that there is a trend of MTSS1 reduction after siRNA-medi-
ated knockdown of AML1-ETO in human t(8;21) positive AML cells (Kasumi-1) (Fig 4A).
Similarly, in patient-derived AML1-ETO positive primary AML cells, MTSS1 mRNA levels
were significantly increased compared to human cord-blood-derived CD34+ myeloid cells (Fig
4B). When assayed for expression, Mtss1 was low (blue squares) in CD34 positive normal cells
but increased in t(8;21) cells (red squares) and this was also true for DNMT3A expression. Re-
versely, expression of DNMT3B was high (red squares) in CD34 positive normal cells but low
in t(8;21) cells (blue and white squares (Fig 4C). Using our own experiments, we next tested
the hypothesis if MTSS1 promoter activity is directly regulated by AML1-ETO, using the same
Kasumi-1 cell line that had suggested a trend of AML1-ETO siRNA mediated downregulation
of MTSS1 (Fig 4A). Luciferase promoter assay using a promoter region containing a fragment
of -276 to -13 bp has previously been described to confer highest Mtss1 expression. The indi-
cated nucleotide position -276 to -13bp is related to the 5´end of annotated Mtss1 mRNA se-
quence with the accession number (NM_014751.5) [21]. Our data demonstrate that MTSS1
promoter activity was significantly higher in human t(8;21) positive AML cells (Kasumi-1)
when compared to various AML1-ETO negative cell lines (Fig 4D). This suggests that the
AML1-ETO fusion molecule is a positive regulator of MTSS1.
Pharmacological inhibition of FLT3-ITD causes upregulation of MTSS1
expression
Finally, since MTSS1 expression was decreased in FLT3-ITD AML patient samples (Fig 1A),
we next studied if there is a potential novel link between MTSS1 and FLT3-ITD mutations.
Strikingly, in a murine AML cell line model of 32D cells that were retrovirally transduced with
a FLT3-ITD overexpressing vector, mRNA levels of MTSS1 were significantly downregulated
30-fold, suggesting that MTSS1 is negatively regulated by FLT3-ITD signaling (Fig 5A). We
next assessed if this downregulation could be reversed using a pharmacological FLT3-ITD in-
hibitor midostaurin (PKC412) which is currently being tested in clinical trials of Flt-ITD posi-
tive AML [22]. Treatment of FLT3-ITD transduced murine 32D cells showed a trend for an
upregulation (p = 0.05) of MTSS1 mRNA levels (Fig 5B). To exclude the possibility that the po-
tential of PKC412 to reverse MTSS1 downregulation was underestimated due to the high levels
of FLT3-ITD in the retrovirally transduced cells, we tested PKC412 in human AML cells carry-
ing a genetic FLT3-ITD mutation (MV4-11). Pharmacological inhibition of FLT3-ITD signifi-
cantly increased MTSS1 mRNA levels approximately 12-fold suggesting that downregulation
of MTSS1 expression by FLT3-ITD is kinase-dependent (Fig 5C). As expected, ATRA was not
able to increase MTSS1 levels in FLT3-ITD positive cells (S3 Fig), suggesting that the effects in
NB4 and MV4-11 cells were truly oncogene-related.
Discussion
Here, we found that MTSS1 expression was high in AML subsets with good prognosis (t(8;21),
inv(16)), and a fraction of NK-AML, but was suppressed in AML subsets with poor outcome
(FLT3-ITD). While earlier studies of MTSS1 had mainly focused on solid cancers and lympho-
mas, this is the first study in myeloid neoplasms providing evidence for an important function
of MTSS1 as a potential tumor suppressor in AML and as a predictor of clinical outcome.
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Fig 4. MTSS1 is positively regulated by AML1-ETO in human AML cells. The gene expression of MTSS1
in human AML cells (Kasumi-1 without transduction (no Trans), scramble siRNA (ctr RNAi) or siRNA
targeting the AML1-ETO translocation is shown (GEO accession numbers GSE15646; A). Similarly, the gene
expression of MTSS1, DNMT3B and 3A are measured in a gene expression analysis of human cord-blood
derived CD34+ cells and patient-derived AML samples with the AML-1 ETO translocation (GEO accession
numbers GSE8023;B andC). Human AML cell lines carrying either a FLT3-ITDmutation (MV4-11), t(15;17)
(NB4), t(8;21) (Kasumi-1) or not defined (U937) were transduced with a MTSS1 firefly / renilla construct and
the MTSS1 promoter activity as a normalized relative ratio was measured (n = 3;D).
doi:10.1371/journal.pone.0125783.g004
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MTSS1 (also termed MIM for “missing in metastasis”) had initially been identified as a gene
that was downregulated in cell lines from metastatic bladder, prostate, and breast cancer as
compared to cell lines from patients with non-metastatic malignancies [23]. This observation
was subsequently confirmed in metastatic specimen from patients with-among others- gastric
Fig 5. FLT3-ITDmediated suppression of MTSS1 is pharmacologically reverted by PKC-412.Mtss1
mRNA levels were measured in murine 32D cells transduced with either empty vector control (EV) or a
FLT3-ITD overexpression vector by qRT-PCR (FLT3-ITD; n = 3; A). Similarly, FLT3-ITD transduced murine
32D cells and human FLT3-ITD+ AML cells (MV4;11) were treated with the pharmacological FLT3-ITD
inhibitor PKC-412 and DMSO control andMTSS1mRNA levels were measured after 24 hours (n = 3; B and
C).
doi:10.1371/journal.pone.0125783.g005
MTSS1 as a New Biomarker in AML Subtypes
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cancer [24], hepatocellular carcinoma [6], breast cancer [7], bladder [21] and prostate cancer
[25]. Several mechanisms for MTSS1 downregulation have been proposed including DNA
methylation [21], transcriptional suppression by DNMT3B [6] or microRNA-mediated effects
[26–31]. Several groups have shown that lack of MTSS1 promotes tumor growth through en-
hanced cell migration and invasion as well as enhanced cell proliferation [6,7,25,30,32]. How-
ever, the exact role of Mtss1 might depend on the cell context and disease type as several
reports have recently reported a possible tumor-promoting function [10,11].
Mice with targeted disruption of MTSS1 (MTSS1 knockout mice) show altered cell polarity,
motility, receptor signaling, and membrane ruffling [14], altered cytoskeleton organization and
cell-cell junctions [33], and they ultimately develop aggressive B cell lymphomas [14]. The
mechanism of lymphomagenesis possibly involved aberrant interactions between B lineage
cells and the lymphoid microenvironment as well as a differentiation block within the B lym-
phoid compartment. Furthermore, MTSS1 was found to be downregulated in cells from pa-
tients with B cell lymphomas and pre-B-ALL [14]. Thus, the data from solid tumors suggest
that MTSS1 may not only be a prognostic AML biomarker but that it may in fact act as an on-
cogene-specific tumor suppressor in AML.
The opposing patterns of DNMT3B and MTSS1, the fact that DNMT3B overexpression is as-
sociated with poor prognosis, and the demonstration that DNMT3B binds directly to the 5
´-flanking region of the MTSS1 promoter to downregulate MTSS1 expression [6] implicate
MTSS1 as one of the major downstream factors of DNMT3B which may at least in part account
for the poor prognosis of DNMT3B-overexpressing AML subsets. It was tempting to speculate
that DNMT3B may be downregulated in AML1-ETO positive cells, and indeed we found this to
be the case (Fig 4C). Functionally, we showed binding of DNMT3B to the MTSS1 promoter in
PML-RARα positive cells while DNMT3B binding to the promoter was absent in AML1-ETO
cells (Fig 4E), further supporting the idea that MTSS1 is released from DNMT3B-mediated re-
pression by AML1-ETO. Future experiments will need to address whether AML1-ETO directly
inhibited DNMT3B expression to allow for high MTSS1 expression. Of course, we cannot
completely rule out that changes in MTSS1 expression were a secondary effect which indicated
favorable versus poor survival. However, besides being a good prognostic biomarker, it is possi-
ble that downregulation of MTSS1 renders cells more resistant to chemotherapy and that alter-
native treatment strategies are needed for AML with lowMTSS1 expression.
One criticism of the present study could be that FLT3-ITD positivity was responsible for the
low expression of MTSS1, the high expression of DNMT3B, and the poor survival in normal
karyotype-AML cases. Unfortunately, data on the FLT3-ITD status were missing in the analy-
sis by Metzeler et al [19]. However, several lines of evidence point to a more general association
of MTSS1 and DNMT3B levels with survival: First, in additional analyses of the 183 AML pa-
tients described by Ley et al [34] and the Cancer genome Atlas Network (2013) and the 2096
patients described by Haferlach et al [35], high expression of MTSS1 was associated with the t
(8;21) and inv(16) AML subsets while MTSS1 expression was low in 7q-deleted cases and t
(11q23)-rearranged cases, both of which are associated with a poor prognosis (not shown). Sec-
ondly, while analysis of the Flt3-ITD negative patients included in the analysis of Verhaak et al
[36] showed a strong trend for decreased survival of DNMT3B high-expressing AML patients
(p = 0.05 each for event-free and overall survival), this was not the case for FLT3-ITD positive
patients (not shown). Together with the fact that DNMT3B expression was higher in
FLT3-ITD-positive vs. FLT3-ITD-negative patients (not shown), this points to FLT3-ITD in-
duced upregulation of DNMT3B or upregulation of DNMT3B by another yet uncharacterized
pathway is a poor prognostic factor in normal karyotype AML.
Taken together, our findings suggest not only that MTSS1 expression is increased in AML
subsets with a more favorable outcome but its expression and potential function can be
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increased by pharmacological approaches allowing for the investigation of future potential al-
ternative therapies, although more in depth genetic and pharmacological studies are required
to carefully dissect the exact function of this adapter and tumor suppressor molecule.
Supporting Information
S1 Fig. ATRA induces maturation and differentiation in NB4 and PML9 transduced U937
cells.Human AML cell lines (NB4, U937 or U937 transduced with PMT RARα) were treated
with either DMSO control or ATRA to induce myeloid differentiation and maturation as as-
sessed by FACS analysis (n = 3).
(PDF)
S2 Fig. Effect of ATRA treatment on Mtss1 expression in PML-RARα positive cells.
PML-RARα positive U937 and empty vector control U937 cells (U937 PMT control) were
treated using ATRA or DMSO as vehicle control and MTSS1 mRNA levels were assessed by
qRT-PCR at indicated time points.
(PDF)
S3 Fig. ATRA treatment does not affect Mtss1 expression in FLT3-ITD positive AML.
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